(Q51355147)

English

Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.

scientific article published on 19 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A Rissanen

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

C P Howard

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

J Botha

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

T Thuren

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

Global Investigators

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

publication date

19 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

14

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

12

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

1088-1096

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Abnormalities in insulin secretion in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1beta and suppressor of cytokine signalling-1 in mouse pancreatic beta cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Blockade of interleukin 1 in type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Altered proinsulin conversion in rat pancreatic islets exposed long-term to various glucose concentrations or interleukin-1beta

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

The potential role of SOCS-3 in the interleukin-1beta-induced desensitization of insulin signaling in pancreatic beta-cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Use of canakinumab in the cryopyrin-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01637.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2012.01637.X

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22726220

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51355147&oldid=1231608053"